Noradrenergic reuptake inhibition in the treatment of pain

Expert Opinion on Investigational Drugs

Volumn 21, Issue 12, 2012, Pages 1827-1834

  Hartrick, Craig T ^a  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenergic reuptake inhibitors; Analgesia; Combination therapy; Neuropathic pain; Noradrenergic reuptake inhibitors; Synergistic action; Topical tricyclic antidepressants; Xen2174

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; AMIKET; AMITRIPTYLINE; ANALGESIC AGENT; BELOXEPIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CAPSAICIN; CLONIDINE; DEXKETOPROFEN; DOXEPIN; DULOXETINE; EB 1020; G PROTEIN COUPLED RECEPTOR; KETAMINE; NORADRENALIN TRANSPORTER; NORADRENERGIC REUPTAKE INHIBITOR; TIZANIDINE; TRAMADOL; UNCLASSIFIED DRUG; VENLAFAXINE; XEN 2174;

ANALGESIA; ANXIETY DISORDER; CANCER PAIN; DEPRESSION; DIABETIC NEUROPATHY; FIBROMYALGIA; GLIA CELL; HUMAN; HYPOTENSION; MIGRAINE; MUSCLE SPASM; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; NORADRENERGIC SYSTEM; PAIN; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; REVIEW; SEDATION; SIDE EFFECT;

ANALGESICS; ANIMALS; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PAIN;

EID: 84868685534     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.731393     Document Type: Review

References (44)

1. Leak JA. Herbal medicine: is it an alternative or an unknown? A brief review of popular herbals used by patients in a pain and symptom management practice setting. Curr Rev Pain 1999;3:226-36
2. Stein C, Machelska H. Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol Rev 2011;63:860-81
3. Jensen TS, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain 2011;152(10):2204-5
4. Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol Clin Exp 2010;25:17-29
5. Pergolizzi JV, Raffa RB, Taylor R, et al. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract 2012; Epub ahead of print
6. Hall FS, Scharzbaum JM, Perona MTG, et al. A greater role for the norepinephrine transporter than the serotonin transporter in murine nociception. Neuroscience 2011;175:315-27
7. Rojo ML, Rodŕiguez-Gaztelumendi A, Pazos A, D́iaz A. Differential adaptive changes on serotonin and noradrenaline transporters in a rat model of peripheral neuropathic pain. Neurosci Lett 2012;515:181-6
8. Hayashida K-I, Eisenach JC. Spinal a2-adrenoceptor mediated analgesia in neuropathic pain reflects brain derived nerve growth factor and changes in spinal cholinergic neuronal function. Anesthesiology 2010;113(2):406-12
9. Schroder W, Vry JD, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14(8):814-21
10. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database of Syst Rev 2012(7):CD008943
11. Hayashida K, DeGoes S, Curry R, Eisenach JC. Gabapentin activates spinal noradrenergic activity in rats and humans and reduces hypersensitivity after surgery. Anesthesiology 2007;106(3):557-62
12. Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011;337(1):312-20
13. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest 2010;120(11):3779-87
14. Alba-Delgado C, Borges G, Sánchez-Blázquez P, et al. The function of alpha-2-adrenoceptors in the rat locus coeruleus is preserved in the chronic constriction injury model of neuropathic pain. Psychopharmacology (Berl) 2012;221:53-65
15. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci 2005;6:521-32
16. Vallejo R, Tilley DM, Vogel L, Benyamin R. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract 2010;10(3):167-84
17. Hutchinson MR, Shavit Y, Grace PM, et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 2011;63:772-810
18. Gutierrez T, Nackley AG, Neely MH, et al. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res 2003;987:176-85
19. Dogrul A, Seyrek M, Yalcin B, Ulugol A. Involvement of descending serotonergic and noradrenergic pathways in CB1 receptor-mediated antinociception. Prog Neuro Psychopharmacol Biol Psychiatry 2012; Epub ahead of print
20. Philipp M, Brede M, Hein L. Physiological significance of a2-adrenergicc receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002;283:R287-95
21. Sawamura S, Kingery WS, Davies MF, et al. Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of a2B adrenoreceptors. J Neurosci 2000;20:9242-51
22. Adachi Y, Aleksic B, Ozaki N. Comparison of pharmacological profiles of serotonin norepinephrine reuptake inhibitors. Clin Neuropsychopharmacol Ther 2010;1:10-15
23. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008;8(1):45-56
24. Kopsky DJ, Keppel Hesselink JM. High doses of topical amitriptyline in neuropathic pain: two cases and literature review. Pain Pract 2012;12(2):148-53
25. Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2011;19(6):833-41
26. Uzaraga I, Gerbis B, Holwerda E, et al. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: a pilot study. Support Care Cancer 2012;20:1515-24
27. McCleane G. Pharmacological management of neuropathic pain. CNS Drugs 2003;17(14):1031-43
28. Elmariah SB, Lerner EA. Topical therapies for pruritus. Semin Cutan Med Surg 2011;30:118-26
29. Hartrick CT, Rozek RJ. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 2011;25(5):359-70
30. Di Lorenzo L, Foti C, Forte AM, et al. The addition of tramadol as a second opioid may improve pain relief in severe osteoarthritis: a prospective study. Pain Pract 2010;10(6):540-7
31. Zegpi C, Gonzalez C, Pinardi G, Miranda HF. The effect of opioid antagonists on synergism between dexketoprofen and tramadol. Pharmacol Res 2009;60:291-5
32. Hartrick CT. Tapentadol immediate release for the relief of moderate-to-severe acute pain. Expert Opin Pharmacother 2009;10(16):2687-96
33. Hache G, Coudore F, Gardier AM, Guiard BP. Monoaminergic antidepressants in the relief of pain: potential therapeutic utility of Triple Reuptake Inhibitors (TRIs). Pharmaceuticals 2011;4:285-342
34. Lucas MC, Weikert RJ, Carter DS, et al. Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain. Bioorg Med Chem Lett 2010;20:5559-66
35. Bymaster FP, Golembiowska K, Kowalska M, et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse 2012;66:522-32
36. Berger B, Adedoyin A, Marion A. Safety, tolerability, and pharmacokinetics of ADL6906, a novel dual norepinephrine reuptake inhibitor and serotonin receptor antagonist. J Pain 2011;12(4S):P54
37. Lewis RJ, Dutertre S, Vetter I, Christie MJ. Conus venom peptide pharmacology. Pharmacol Rev 2012;64:259-98
38. Fedosova AE, Moshkovskiic SA, Kuznetsovac KG, Oliverab BM. Conotoxins: from the biodiversity of gastropods to new drug. Biomed Chem 2012;6(2):107-22
39. Lewis RJ. Discovery and development of the c-conopeptide class of analgesic peptides. Toxicon 2012;59:524-8
40. Tammimaki A, Mannisto PT. Catechol-O-methyltransferase gene polymorphism and chronic human pain: a systematic review and meta-analysis. Pharmacogenet Genomics 2012; [Epub ahead of print]
41. Hartrick CT, Rodŕiguez Hernandez Jr. Tapentadol for pain: a treatment evaluation. Expert Opin Pharmacother 2012;13(2):283-6
42. Hartrick CT, Gatchel RJ, Conroy S. Identification and management of pain medication abuse and misuse: current state and future directions. Expert Rev Neurother 2012;12(5):601-10
43. Yalcin I, Tessier L-H, Petit-Demoulière N, et al. b2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. Neurobiol Dis 2009;33:386-94
44. Zhao X, Xu Y, Zhao Q, et al. Curcumin exerts antinociceptive effects in a mouse model of neuropathic pain: descending monoamine system and opioid receptors are differentially involved. Neuropharmacology 2012;62:843-54